Romidepsin (FK228, Depsipeptide)

Catalog No.S3020 Synonyms: FR 901228, NSC 630176

Romidepsin (FK228, Depsipeptide) Chemical Structure

Molecular Weight(MW): 540.7

Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.

Size Price Stock Quantity  
USD 157 In stock
USD 477 In stock
USD 697 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 20 Publications

6 Customer Reviews

  • Concentration over time for each dose cohort of romidepsin (B).

    Blood, 2018, 131(4):397-407. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

    PBMCs from a patient were incubated with diverse agents (2 μM Compound E, 2 nM Bortezomib and 1nM Romidepsin) for 48 hours. Apoptosis detection was performed by Annexin V/PI staining and analyzed by flow cytometry. Annexin V+/PI− (lower right quadrant) areas stand for early apoptotic cells, and Annexin V+/PI+ (upper right quadrant) areas stand for late apoptotic or necrotic cells.

    Leukemia, 2015, 29(3):556-66. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

  • Effects of combination of bort/romidepsin on HDAC6 inhibition and activation of ER stress signaling. HA cells were treated with combination of 15 nM bortezomib and 5 nM romidepsin or either drug alone for 24 hr. Expression of CHOP/GADD153 (green signals) and cleaved PARP (red signals) was detected by immunofluorescent staining. DAPI (blue signals) stained the cell nuclei.

    Int J Cancer 2014 135(12):2950-61. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

    An HIV-Gag-SLYNTVATL-specific CTL clone was labeled with Alexa-Fluor555 conjugated cholera toxin subunit B either cultured with 500 nM SAHA or 25 nM romidepsin for 20 hours, or maintained as an untreated control. These effector cells were combined with SLYNTVATL peptide pulsed target cells, matched on the restricting allele, in a collagen matrix medium containing sytox green viability dye. These mixtures were then plated in three separate wells of an 8-well cover slip and imaged by time-lapse brightfield and fluorescent microscopy. A. Shown are representative fields of view from the no treatment (upper panel), 500 nM SAHA (middle panel), and 25 nM romidepsin (lower panel) conditions advancing in time from left to right. Time stamps are given in hh[ratio]mm format. Clones described in the results are indicated with yellow arrows and killed target cells are indicated with white arrows in the upper right panel.

    PLoS Pathog 2014 10(8), e1004287. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

  • PLZF-RARa–nonexpressing and -expressing PLZFRARβ3 cells were treated with 5 nmol/L romidepsin for the indicated time points. Induction of the DNA DSB marker γH2AX was measured by Western blotting. β-Actin was used as a loading control.

    Mol Cancer Ther 2013 12(8), 1591-604. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

    Impacts of chromopeptide A and FK228 on G2/M transition regulators. PC3 and LNCaP cells were treated with chromopeptide A or FK228 at indicated concentrations for 24 h, and cells lysates were immunoblotted with the indicated antibodies.

    Acta Pharmacol Sin, 2017, 38(4):551-560. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.
Features More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
Targets
HDAC1 [1]
(Cell-free assay)
HDAC2 [1]
(Cell-free assay)
36 nM 47 nM
In vitro

Unlike TSA, the active form redFK of Romidepsin strongly inhibits HDAC1 and HDAC2 with IC50 of 1.6 nM and 3.9 nM, respectively, but is relatively weak in inhibiting HDAC4 and HDAC6 with IC50 25 nM and 790 nM, respectively. Romidepsin is 17-23 times weaker than redFK in inhibiting these HDACs with IC50 of 36 nM, 47 nM, 510 nM, and 14 μM, respectively. Romidepsin treatment in HeLa cells induces histone acetylation and p21 expression with EC50 of 3.0 nM, more strongly than redFK with EC50 of 11 nM due to the instability of redFK. [1] In addition to G2/M arrest, Romidepsin treatment causes cyclin D1 downregulation and a p53-independent p21 induction, leading to inhibition of CDK and dephosphorylation of Rb resulting in growth arrest in the early G1 phase. [2] Romidepsin is 100 times more potent than TSA and 1,000,000 times more potent than butyrate in inhibiting the proliferation of the A549 cells. [3] Romidepsin inhibits the growth of U-937, K562, and CCRF-CEM cells with IC50 of 5.92 nM, 8.36 nM, and 6.95 nM, respectively. [5] Romidepsin promotes apoptosis in chronic lymphocytic leukemia (CLL) cells at a concentration corresponding to that at which H3 and H4 acetylation and HDAC inhibition occurs, selectively involving activation of caspase 8 and effector caspase 3, as well as down-regulation of c-FLIP protein. [6] In 11 of 13 (85%) renal cell carcinoma cell lines and in 16 of 37 (43%) other cancer cell lines, Romidepsin treatment up-regulates tumor death receptors, and potentiates natural killer (NK)-mediated tumor killing. [7] Romidepsin exhibits concentration-dependent cytotoxicity against a panel of mantle cell lymphoma (MCL) cell lines. [9]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SU-DHL4 NUfufpI6S2WubDDWbYFjcWyrdImgRZN{[Xl? Mn;CNk42NTF3IH7N MV:3NkBp M3PxNYlv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? MYKyOVc6ODlyNx?=
U2932  Ml3tR4VtdCCYaXHibYxqfHliQYPzZZk> NHn5cmczNjVvMUWgcm0> NHjDblI4OiCq Mli0bY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? Mmi1NlU4QTB7MEe=
OCI-LY7 M3Pme2NmdGxiVnnhZoltcXS7IFHzd4F6 MlvLNk42NTF3IH7N NX:0V2p5PzJiaB?= Mlz5bY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? M{DYRlI2PzlyOUC3
Farage NWPUZWNTS2WubDDWbYFjcWyrdImgRZN{[Xl? MYKyMlUuOTVibl2= NFvSOJU4OiCq NYfae2YycW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?= NVrmNVNpOjV5OUC5NFc>
LY7/EBV NFnqW5dE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M1qz[lIvPS1zNTDuUS=> MVe3NkBp NXKwUnJxcW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?= NYDrZXFJOjV5OUC5NFc>
U2932/EBV MVzD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MV[yMlUuOTVibl2= M4n6U|czKGh? MWXpcoR2[2W|IHP5eI91d3irY3n0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh NYGzTHplOjV5OUC5NFc>
HCT116 Mm\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jxT|UuPTByMDDuUS=> NUfxPJZWOjRiaB?= NIfhXJpFVVOR MWjpcoR2[2W|IHPlcIwh\GWjdHigbY4h[SClb37j[Y51emG2aX;uMYRmeGWwZHXueEBu[W6wZYK= M1LDfVI2PDl{NUG1
ACH-2 Mkm4SpVv[3Srb36gRZN{[Xl? M1;RW|EuQSCwTR?= MojINlQhcA>? NI\1VoVqdmS3Y3XzJGhKXi1zIFXuekBmgHC{ZYPzbY9v NYGxb3g2OjVzNEm0Olc>
MCF-10A NEfTSJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnm0TWM2OD1yLkG3xtExNjBzIH7N MYeyOFk2PDh3Nh?=
MCF-7 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4T3UGlEPTB;MT6xNOKyOC5{MDDuUS=> MlfSNlQ6PTR6NU[=
SK-BR-3 NVLCV|ZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XWfWlEPTB;MT6wNOKyOC5|NTDuUS=> MmXKNlQ6PTR6NU[=
MDA-MB-231 Mn\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;jdHIxUUN3ME2wMlY5yrFyLkG0JI5O MWWyOFk2PDh3Nh?=
PC3 NFr1ZllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\y[5BKSzVyPUGuOlXDuTBwM{Wgcm0> NG\meXgzPDl3NEi1Oi=>
HCT116 NIHsbYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXHTWM2OD1zLkCwxtExNjByIH7N NIXiNHczPDl3NEi1Oi=>
HCT116-p21-/- MlH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTFwMkdCtVAvOzdibl2= MX:yOFk2PDh3Nh?=
S1 NXnRdYJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M176NGlEPTB;Nz62O:KyOC5{OTDuUS=> M4\5TlI1QTV2OEW2
SW620 MlH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTBwOURCtVAvOjlibl2= NVLnZ5BPOjR7NUS4OVY>
LOX-IMVI NV7lVpZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DSUGlEPTB;MD64O:KyOC5yMzDuUS=> M1f1U|I1QTV2OEW2
UACC-62 M3\Qb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTBwNUdCtVAvOTZibl2= M3HOVFI1QTV2OEW2
MDA-MB-435 NXXBNJpPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTBwOUFCtVAvODZibl2= MW[yOFk2PDh3Nh?=
SF-295 NFLDd3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPHXppKSzVyPUCuPFjDuTBwMUWgcm0> M2WxN|I1QTV2OEW2
A549 MlLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nHVmlEPTB;MT6yOuKyOC5{NDDuUS=> MXeyOFk2PDh3Nh?=
H460 NX3Zd|htT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nFXGlEPTB;Mj61POKyOC56MDDuUS=> NGXPengzPDl3NEi1Oi=>
EKVX NV3CN5BxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEH2V4dKSzVyPUGuN|PDuTBwM{Sgcm0> MX2yOFk2PDh3Nh?=
H146 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnUNGZKSzVyPUCuNlLDuTBwMEegcm0> NWjsU2ZCOjR7NUS4OVY>
H526 NG\4XGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTBwMUZCtVAvODNibl2= M2LiS|I1QTV2OEW2
HuT-78 MkG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoWxTWM2OD1zLkezxtExNjR2IH7N MlrINlQ6PTR6NU[=
HA NUi5dJFMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnCUo5QOC54MkWtNVBvVQ>? MUi0PEBp NUTYW2JOcW6mdXPld{BiKHOrZ37p[olk[W62bImgd5Rzd26pZYKgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25iY3:teJJm[XSnZDD3bZRpKGKxcoTlfo9ucWJ? NIHWeWwzPDd5MUWxNC=>
MS-275 MonSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX[xUm9TOC54MkWtNVBvVQ>? MmHXOFghcA>? M1nUWolv\HWlZYOgZUB{cWewaX\pZ4FvfGy7IIP0do9v\2W{IHnubIljcXSrb36gc4Yh[2WubDDwdo9tcW[ncnH0bY9vKGOxLYTy[YF1\WRid3n0bEBjd3K2ZYrvcYlj NWruPHY2OjR5N{G1NVA>
CD4 T MmjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoflOFghcA>? NFLBOWtGSzVyPUSuOeKyOS5yIH7N NWC4[WlFOjR5MkK0OVQ>
CD4 T MmHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLSOFghcA>? NFLRbVRESzVyPUGwO:KyOTJ4IH7N NX36SJZoOjR5MkK0OVQ>
CD4+ T MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrYSGJYTUN3ME2zJI5O MmnvNlQ1QTVzMEW=
A549 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXS4[lBTOTEkgKOxNFDDqG6P NX3LVIZWOjRxM{[vOFghcA>? MUDpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJINwdmOnboTyZZRqd25vIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? NUjiS3F5OjR2OEW3PVk>
JJN3 M4HtcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LyW|I1NzR6IHi= NFTVco9GSzVyPEJihKlvVTtiNElihKlp M{PMVFI1ODNyMUWw
OPM-2 MlLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYCyOE81QCCq NFrWe5ZGSzVyc{2x5qCKdk19IES45qCKcA>? NUf4fJZvOjRyM{CxOVA>
RPMI-8226 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvyPFJGOjRxNEigbC=> NUnmUWtyTUN3MIO9NU456oDLbl27JFQ56oDLaB?= NELSXnMzPDB|MEG1NC=>
U266 NGq3U49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\UNlQwPDhiaB?= MVfFR|Uxez1zMPMAjY5OQyB2OPMAjYg> NWPDZ3dkOjRyM{CxOVA>
CA46 NGXmbXpCeG:ydH;zbZMhSXO|YYm= NWHJTpVHPiCq NEjIUYRqdmS3Y3XzJIJtfW62IHHwc5B1d3Orcx?= M3Gy[|I{QTZ4MU[0
DG75 MmW0RZBweHSxc3nzJGF{e2G7 NVXTW3Y4PiCq NHe0NnNqdmS3Y3XzJI5wKGGyb4D0c5Nqew>? M{nFdFI{QTZ4MU[0
Ramos M3r3[WFxd3C2b4Ppd{BCe3OjeR?= M1TG[FYhcA>? NGTwWIRqdmS3Y3XzJIV5fGWwc3n2[UBieG:ydH;zbZM> NIG0W|gzOzl4NkG2OC=>
ST486 NWfqe|Z5SXCxcITvd4l{KEG|c3H5 M2PlbFYhcA>? MYLpcoR2[2W|IHX4eIVve2m4ZTDhdI9xfG:|aYO= M2W0[FI{QTZ4MU[0
HuT78 MYrBdI9xfG:|aYOgRZN{[Xl? NUTGWotrOS9zMD:xNFAhdk1? MlfPOFghcA>? MX7pcoR2[2W|IHHwc5B1d3OrczDheEAyKG6P NWTsNWp3OjN3M{K3N|I>
DpVp35 M33PZ2Fxd3C2b4Ppd{BCe3OjeR?= MkLQNU8yOC9zMECgcm0> MVi0PEBp NGi5UnlqdmS3Y3XzJIJtfW62IHHwc5B1d3Orcx?= NVzQZWg3OjN3M{K3N|I>
DpVp50 MYrBdI9xfG:|aYOgRZN{[Xl? NWfvb3FCOS9zMD:xNFAhdk1? M3;icVQ5KGh? NFziellqdmS3Y3XzJIJtfW62IHHwc5B1d3Orcx?= MonuNlM2OzJ5M{K=
DpP75  NYL2bVNwSXCxcITvd4l{KEG|c3H5 Mk\xNU8yOC9zMECgcm0> NVHWVY1bPDhiaB?= NFXEZYRqdmS3Y3XzJIJtfW62IHHwc5B1d3Orcx?= Ml3sNlM2OzJ5M{K=
SKOV-3 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1njSlHjiJN{MH7N NXPZZllDPzJiaB?= M4jyW2ROW09? M1r3WZJm\HWlZYOgZ4VtdCC4aXHibYxqfHliYXzvcoUh[W6mIHPvcYJqdmWmIIfpeIgh[2m|cHzheIlv M1fUWVI{ODFyM{S4
Brca1 WT MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUOx5qCUOjCwTR?= MmfpO|IhcA>? NXnvRZo{TE2VTx?= NX21[lJoemWmdXPld{Bk\WyuII\pZYJqdGm2eTDhcI9v\SCjbnSgZ49u[mmwZXSge4l1cCClaYPwcIF1cW5? MUOyN|AyODN2OB?=
Brca1 Null M3P6WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXZVGwy6oDVMkDuUS=> MkfrO|IhcA>? NYDuOVMzTE2VTx?= M3LadpJm\HWlZYOgZ4VtdCC4aXHibYxqfHliYXzvcoUh[W6mIHPvcYJqdmWmIIfpeIgh[2m|cHzheIlv M4SyfVI{ODFyM{S4
OVCAR-8  Ml;HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7BNgKBmzJybl2= NEnl[Ik4OiCq NIfTflVFVVOR MlXEdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCjbH;u[UBidmRiY3;tZolv\WRid3n0bEBkcXOybHH0bY4> MnzlNlMxOTB|NEi=
NCI/ADR-RES MkLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XBeVHjiJN{MH7N MXe3NkBp MkXqSG1UVw>? M{fOUJJm\HWlZYOgZ4VtdCC4aXHibYxqfHliYXzvcoUh[W6mIHPvcYJqdmWmIIfpeIgh[2m|cHzheIlv NVXGNFY2OjNyMUCzOFg>
HCT116 MmTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV70V2lnPSCwTT21NEDPxE1? NXLqSYJKOjRiaB?= NEXMdJFFVVOR M1\SWolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz MYmyNlkzPDl3OB?=
RKO M2nn[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3q4UlUhdk1vNUCg{txO MXeyOEBp MmTiSG1UVw>? NE[w[mRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? NXK4dodCOjJ7MkS5OVg>
CO115 M1rseWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHvcJNDPSCwTT21NEDPxE1? NWDwcnYyOjRiaB?= MnjHSG1UVw>? NIH3TnlqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? MXeyNlkzPDl3OB?=
HFS NFvUR3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrYVpI2KG6P NFu0VlIzPC92OD:3NkBp M{L5eolvcGmkaYTzJINmdGxiZ4Lve5RpKHSrbXWt[IVx\W6mZX70cJk> NX;jc45sOjJzME[yPFI>
LNCaP M1rN[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDvb4k2KG6P NWrUPXhXOjRxNEivO|IhcA>? MoHRbY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZT3k[ZBmdmSnboTsfS=> MUiyNlExPjJ6Mh?=
A549 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLabY5SPSCwTR?= NYfxXGFGOjRxNEivO|IhcA>? MVjpcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nLXTldIVv\GWwdHz5 MWWyNlExPjJ6Mh?=
697  NHjZRplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|Ux6oDLPfMAjVIvPcLibl2= MX[yNVU{QDJzNh?=
697-R NV\XVpdET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITi[|BKSzVy4pEJQgKBkThwNtMgcm3DqA>? NVfvVVY3OjF3M{iyNVY>
HUT78 NWHvUm5KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzmTFVvUUN3ME2xJI5O NVvrS40{OjFzOUi1OFU>
THJ-16T NHL6cXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rrUFEhdk1? NXrEcoJWOjRiaB?= MXLpcohq[mm2czDj[YxtKGe{b4f0bC=> MWSyNFgyODV4OB?=
HCT116 MUPGeY5kfGmxbjDBd5NigQ>? M1X5UlIxKG6P MVu4JIg> NX;hXG04dW:mdXzheIV{KHS{YX7zZ5JqeHRibHX2[Yx{KG[xcjDoeY5lemWmczDv[kBo\W6nczDpckBmcXSqZYKg[Ilz\WO2aX;u M1f0c|IxPzN7NEW0
B104  MmHOSpVv[3Srb36gRZN{[Xl? NEDCPVQzKG6P MUiyOE81QC95MjDo NEnEN45qdmO{ZXHz[ZMhfGinIIP1doZi[2ViZYjwdoV{e2mxbjDv[kBETDJywrC= NUPFdlNuOjB4OE[1NFU>
HL-60  Ml\5R5l1d3SxeHnjbZR6KEG|c3H5 M4e0WFEuPTByIH7N M1fJNVI1KGh? NH7zNoZqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi Ml7xNlA3OjRzNkO=
HP100 MYHDfZRwfG:6aXPpeJkhSXO|YYm= NV;aTGd1OS13MECgcm0> NVvwbZNJOjRiaB?= NEHGb4hqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi Mn\zNlA3OjRzNkO=
HL-60  NVXB[pJPTnWwY4Tpc44hSXO|YYm= MUKxNEBvVQ>? MXm0M|YwOTZiaB?= M{TvS4lv\HWlZYOgeIhmKGenbnXyZZRqd25ib3[gbJllem:pZX6gdIVzd3irZHWg[pJwdSB2aB?= MmPINlA3OjRzNkO=
HP100 NYH2RmJkTnWwY4Tpc44hSXO|YYm= M4rBZ|ExKG6P MWq0M|YwOTZiaB?= NV[3TXdIcW6mdXPld{B1cGViZ3Xu[ZJifGmxbjDv[kBpgWS{b3flckBx\XKxeHnk[UBnem:vIETo NEfPT5AzODZ{NEG2Ny=>
HL-60  NWO2NYdOTnWwY4Tpc44hSXO|YYm= MUmxNE02ODBibl2= MkW1OEBp NIHDR49l\WO{ZXHz[ZMhfGinIHjpd5RwdmViZHXhZ4V1gWyjc3WgLGhFSUNrIHHjeIl3cXS7wrC= NFHaPJkzODZ{NEG2Ny=>
HP100 MUPGeY5kfGmxbjDBd5NigQ>? NYOyVWRKOTBvNUCwJI5O NHXDe5o1KGh? M1jUe4Rm[3KnYYPld{B1cGViaHnzeI9v\SCmZXHj[ZR6dGG|ZTCoTGRCSyliYXP0bZZqfHoEoB?= NHXzPVczODZ{NEG2Ny=>
11z MmrKT4lv[XOnIFHzd4F6 NYHJZXVXOy1zMECgcm0> NEPWRYhz\WS3Y3XzJGhFSUNiZX76fY1ifGmlIHHjeIl3cXS7IDjJR|UxyqB;IE[uOUDDuSByLk[gco1wdC:OKR?= NEjxN5ozODZyNUG0OC=>
SKOV-3 M{\lPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjvdGg1NzhxMU[gcm0> M{nEXVQ5KGh? M3LOSolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz M37pTlIxPDB2NU[0
OVCAR-3 MnL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7CRYI1NzhxMU[gcm0> NX;OUHduPDhiaB?= NFXMUHZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? NFLpRYwzODRyNEW2OC=>
HBL-2 MkjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NES1VGwzNTFyIH7N MnzNNlQhcA>? MULJR|UxRTRwMzDuUS=> M13URVIxODZ6MEiw
Jeko-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mof5Nk02OCCwTR?= MmP6NlQhcA>? NGDLUlBKSzVyPUGxJI5O MV:yNFA3QDB6MB?=
Granta-519 NYTET|RqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLqVWY2NTRyIH7N M1vGSlI1KGh? Mn\wTWM2OD13OD61JI5O NGHk[lEzODB4OEC4NC=>
L1236 MWjDfZRwfG:6aXPpeJkhSXO|YYm= MkC1NUBvVS1zMECg{txO MWC0PEBp MkX1SWM2OD1yLkC3JO69VQ>? MnvHNVkzOzN2N{C=
L428 M1ezbmN6fG:2b4jpZ4l1gSCDc4PhfS=> NGDUUIgyKG6PLUGwNEDPxE1? M4TuPVQ5KGh? MXTFR|UxRTBwNEOg{txO MlOzNVkzOzN2N{C=
KM-H2 NFrNTZREgXSxdH;4bYNqfHliQYPzZZk> MnjkNUBvVS1zMECg{txO NGnxVWs1QCCq NF3Dd2RGSzVyPUCuOVgh|ryP M4nBPVE6OjN|NEew
L540Cy NXfkSGRkS3m2b4TvfIlkcXS7IFHzd4F6 NHK4W2oyKG6PLUGwNEDPxE1? M{WzPVQ5KGh? NXfuV5Z2TUN3ME2wMlE3KM7:TR?= NVLXZ4tJOTl{M{O0O|A>
G401 MXLGeY5kfGmxbjDBd5NigQ>? M4HnSlExKG6P MlTiNlQwPDhxN{KgbC=> Mm\XSG1UVw>? MWrpcoNz\WG|ZYOgR2RMVjGFIHX4dJJme3Orb36= MWixPVIzOTV6Nh?=
STM91-01 NUC4ZpVWTnWwY4Tpc44hSXO|YYm= NVT0b4xTOTBibl2= MVeyOE81QC95MjDo NVOwd5F1TE2VTx?= MoHzbY5kemWjc3XzJGNFU05zQzDlfJBz\XO|aX;u Mk\JNVkzOjF3OE[=
SJSC  NXTDUHI5TnWwY4Tpc44hSXO|YYm= NIfTVXIyOCCwTR?= NFe4UIozPC92OD:3NkBp NEX1b3RFVVOR NXTRUWdqcW6lcnXhd4V{KEOGS16xR{BmgHC{ZYPzbY9v NInsdlgyQTJ{MUW4Oi=>
BT16  MlrnSpVv[3Srb36gRZN{[Xl? M{LvOlExKG6P NYTRWZU5OjRxNEivO|IhcA>? MlPoSG1UVw>? NGG1Wm5qdmO{ZXHz[ZMhS0SNTkHDJIV5eHKnc4Ppc44> Moj6NVkzOjF3OE[=
NCI-H1299 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M123eWlEPTB;ND62xtExNjJibnevcYw> NHXUOWgyQTF5OUi5NC=>
NCI-2882 MnfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mof4TWM2OD1zLkdCtVAvODRibnevcYw> NV;INVN[OTlzN{m4PVA>
HCC95 Mm[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3FR|d7UUN3ME2yMlXDuTBwMEWgcocwdWx? MXKxPVE4QTh7MB?=
NCI-H23 NFXxe2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTJwOdMxNE4zKG6pL33s M2\BeVE6OTd7OEmw
NCI-H157 M3HmNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTFwNtMxNE4xOiCwZz;tcC=> MYOxPVE4QTh7MB?=
NCI-H460 NV;0dXoyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPTTWM2OD1{LkJCtVAvODdibnevcYw> M{XjVFE6OTd7OEmw
NCI-H1975 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37PXGlEPTB;MT6zxtExNjB2IH7nM41t NXTR[|RCOTlzN{m4PVA>
NCI-H820 M2jZemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTJwNNMxNE4yKG6pL33s NELOSFUyQTF5OUi5NC=>
NCI-H1650 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LhOGlEPTB;ND65xtExNjNibnevcYw> Mlf3NVkyPzl6OUC=
DTC1 Mkj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\RbZdKSzVyPUCuOVEhdk1? NUXFcYpkOTh3Nk[yOFY>
KAO NI\lTGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2e0eGlEPTB;MD65NUBvVQ>? M1PySlE5PTZ4MkS2
SU-CCS-1 NXnWV|g4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTlPIpHUUN3ME2wMlg6KG6P M1Tk[|E5PTZ4MkS2
SYO-1 MkPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHj6OJhKSzVyPUCuOlchdk1? MX6xPFU3PjJ2Nh?=
FUJI MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTFwM{Ggcm0> NEW2NnQyQDV4NkK0Oi=>
SKNMC NIqyNVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzjTnVuUUN3ME2xMlE4KG6P NX63dXh2OTh3Nk[yOFY>
402-91 M{T1[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4S0VGlEPTB;MT6yOkBvVQ>? NI\XNY4yQDV4NkK0Oi=>
1765-92 NXr4V4d7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jo[WlEPTB;MT63O{BvVQ>? MVixPFU3PjJ2Nh?=
JN-DSRCT-1 M3jOfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnqTWM2OD1zLkK1JI5O MU[xPFU3PjJ2Nh?=
NMS-2PC NHPBU2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvnTWM2OD1yLkixJI5O NGjnRXAyQDV4NkK0Oi=>
HL60 M{noWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\pRphKSzVyPUGuPFYhdk1? M{XlRlE5PTZ4MkS2
A549 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzVcnhKSzVyPUOuNlQhdk1? NXfRNHp5OTh3Nk[yOFY>
SW480 NFXUR3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jIdGlEPTB;Mj62PUBvVQ>? NXrKdoZYOTh3Nk[yOFY>
MCF7 M1LIOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37vfmlEPTB;Mz61OUBvVQ>? Mo\GNVg2PjZ{NE[=
PC-3 MmD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLIVlY6UUN3ME2yMlUyKG6P Ml3MNVg2PjZ{NE[=
MMRU M1HOcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfTdHZKSzVyPUKuOVchdk1? MWOxPFU3PjJ2Nh?=
Hs68 M3\ue2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoH0TWM2OD1-MUCgcm0> MVixPFU3PjJ2Nh?=
hMSC-001F Ml\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{D5dGlEPTB;PkGwJI5O MmTLNVg2PjZ{NE[=

... Click to View More Cell Line Experimental Data

In vivo Romidepsin treatment potently inhibits the neovascularization of chick embryo and that of adult mice in the Matrigel plug assay. [4]Administration of Romidepsin at 0.1-1 mg/kg twice a week significantly prolongs the survival of mice bearing U-937 lymphoma, with median survival times of 30.5 (0.56 mg/kg) and 33 days (0.32 mg/kg), respectively (vs. 20 days in control mice). [5]

Protocol

Kinase Assay:

[1]

+ Expand

HDAC-inhibitory activity:

For the enzyme assay, 10 μL of [3H]acetyl-labeled histones (25,000 cpm/10 μg) are added to 90 μL of the HDAC enzyme fraction extracted from 293T cells overexpressing HDAC1 or HDAC2 in the presence of increasing concentrations of Romidepsin, and the mixture is incubated at 37 °C for 15 minutes. The enzyme reaction is linear for at least 1 hour. The reaction is stopped by the addition of 10 μL of concentrated HCl. The released [3H]acetic acid is extracted with 1 mL of ethylacetate, and 0.9 mL of the solvent layer is taken into 5 mL of aqueous counting scintillant II solution for determination of radioactivity. The IC50 values are determined from at least three independent dose-response curves.
Cell Research:

[3]

+ Expand
  • Cell lines: HL60, Jurkat, A549, and MCF-7
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to various concentrations of Romidepsin for 72 hours in 96-well plates. 20 μL of 5 mg/mL MTT solution in PBS is added to each well for 4 hours. After removal of the medium, 170 μL of DMSO is added to each well to dissolve the formazan crystals. The absorbance at 540 nm is determined. In addition, cells are incubated with trypan blue, and the numbers of blue (dead) cells and transparent (live) cells are counted in a hemocytometer. For cell cycle analysis, cells are incubated for 30 minutes in propidium iodide staining solution containing 0.05 mg/mL propidium iodide, 1 mM EDTA, 0.1% Triton X-100, and 1 mg/mL RNase A in PBS. The suspension is then passed through a nylon mesh filter and analyzed on a Becton Dickinson FACScan.


    (Only for Reference)
Animal Research:

[5]

+ Expand
  • Animal Models: Male scid mice inoculated i.p. with U-937 cells
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: ~1 mg/kg once or twice a week
  • Administration: Treated i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 10 mg/mL (18.49 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5%Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 540.7
Formula

C24H36N4O6S2

CAS No. 128517-07-7
Storage powder
in solvent
Synonyms FR 901228, NSC 630176

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03770000 Recruiting T Cell Lymphoma Rhizen Pharmaceuticals SA March 2019 Phase 1|Phase 2
NCT03770000 Recruiting T Cell Lymphoma Rhizen Pharmaceuticals SA March 2019 Phase 1|Phase 2
NCT03703375 Recruiting Lymphoma T-Cell Celgene November 6 2018 Phase 3
NCT03593018 Recruiting Relapsed Angioimmunoblastic T-Cell Lymphoma|Refractory Angioimmunoblastic T-cell Lymphoma The Lymphoma Academic Research Organisation|Celgene November 9 2018 Phase 3
NCT03703375 Recruiting Lymphoma T-Cell Celgene November 6 2018 Phase 3
NCT03593018 Recruiting Relapsed Angioimmunoblastic T-Cell Lymphoma|Refractory Angioimmunoblastic T-cell Lymphoma The Lymphoma Academic Research Organisation|Celgene November 9 2018 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products4

Tags: buy Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) supplier | purchase Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) cost | Romidepsin (FK228, Depsipeptide) manufacturer | order Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID